Study #2020-0952
Pre-Transplant Immunosuppression for Matched Sibling and Related Haploidentical Hematopoietic Cell Transplantation for Patients with Severe Hemoglobinopathies
MD Anderson Study Status
Enrolling
Treatment Agent
Bortezomib, Busulfan, Cyclophosphamide, Dexamethasone, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Mycophenolate Mofetil, Rituximab, Tacrolimus
Description
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies). PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the body to support blood cell production. PTIS and HCT may help to control severe hemoglobinopathies.
Information and next steps
Disease:
Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
Study phase:
I (Early)
Physician name:
Kris Mahadeo
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.